Research

Cutting-edge gene therapies for eye diseases can help improve quality of life, extend the working lives of patients, and reduce treatment costs.

A global network, coordinated by Oxford University, is helping to ensure health research benefits low-income countries.

Researchers at the Department of Chemistry are developing technologies to make recycling plastics easy, clean and affordable – promoting a truly ‘circular economy’ for the material.

The Medical Sciences Division’s Business Partnerships Office is celebrating ten years of developing productive relationships and supporting effective collaborations with industry.

Researchers from the University of Oxford and their partners have today reported findings from a Phase IIb trial of a candidate malaria vaccine, R21/Matrix-M, which demonstrated high-level efficacy of 77% over 12-months of follow-up.

Our vaccine work is progressing quickly.

Our vaccine work is progressing quickly.

The Phase I trial, which will enrol 30 healthy volunteers aged 18–40, will investigate the level of immune system responses generated by the vaccine using this delivery technique, as well as monitoring safety and for any adverse reactions.

The Arctic Bears Project is being led by Professor Douglas Clark, of the University of Saskatchewan, in collaboration with penguinologist Dr Tom Hart of Oxford’s Department of Zoology.

Our vaccine work is progressing quickly.

Azithromycin and doxycycline are two commonly used antibiotics investigated as separate treatments in the trial. Both drugs are being used by some doctors in the hope of treating COVID-19 in the early stages of the illness.

A new interpretation of the survey behind Domesday Book – the record of conquered England compiled on the orders of William the Conqueror in 1086 – has emerged from a major new study of the survey’s earliest surviving manuscript.

Our vaccine work is progressing quickly.

Our vaccine work is progressing quickly.

These findings are reported in two papers, both released in the peer-reviewed journal Nature Medicine.

The MBRRACE programme is influencing policy and services to support pregnant women and prevent maternal deaths.

Software developed by an international team including Dr Alex Teytelboym from Oxford University is helping to resettle refugees in communities where they are more likely to flourish.

Our vaccine work is progressing quickly.

Researchers at Oxford Vaccine Group have developed machine learning software to predict the efficacy of flu vaccines, offering huge potential for other vaccine research.

Kirsten Shepherd-Barr and colleagues have developed the award-winning LitHits app, which allows users to access great literature in unexpected ways.